Drug intelligence / Profile preview

H1152

Development stage
Preclinical
Lead developer
Mitsubishi Tanabe Pharma
Modality
Small Molecules
Administration
In Vitro, Experimental (animal Injections)
01

Overview

H1152 is a highly selective, potent, and ATP-competitive small molecule inhibitor of Rho-kinase (ROCK), primarily inhibiting ROCKII with markedly less affinity for other kinases. It is membrane permeable and exhibits much greater specificity and potency for ROCK enzymes than earlier ROCK inhibitors such as Y27632. H1152 displays biological activities such as inhibiting stress fiber formation, promoting neurite extension, preventing fragmentation of apoptotic cells, displaying pro-erectile effects in animal models, and reducing neuropathic pain. It is widely used as a research tool for studying ROCK signaling, neuronal differentiation, and cell motility and contraction[1][2][3][4][6].

Other names
H-1152 dihydrochlorideH1152 dihydrochlorideH 1152 dihydrochloride(S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride(S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine dihydrochlorideH-1152P . 2HClH1152P . 2HClH 1152P . 2HCl
02

Targets

MLCK (Myosin light chain kinase)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)PKA (Cyclic amp-dependent protein kinase)PRKCI (Protein kinase C iota)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)

Beyond the preview

Go deeper on H1152.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on H1152.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call